Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

Nov 9 2023

Our CEO, Peter Nestorov, and Sahar Sala, our Head of Quality Assurance & Regulatory Affairs at Scailyte, engaged in a thought-provoking conversation about the recent news that US President Biden had issued an Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence.

Data integrity and equity, risk management activities, and good documentation are at the heart of our discussion. It’s important to recognize that AI involves two critical aspects: data and algorithms.

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI landscape.

Watch the full discussion on YouTube:

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals

Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...

Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit�...

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...